Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| TBC | filgrastim | Prevention or treatment of neutropenia in various indications | Cancelled | |||
| TBC | filgrastim | Cancelled | ||||
| TBC | daprodustat | Anemia due to chronic kidney disease | Withdrawn | |||
| TBC | abaloparatide | Osteoporosis, postmenopausal women | Withdrawn | |||
| TBC | tirzepatide | Diabetes mellitus, type 2 | Cancelled | |||
| TBC | ferumoxytol | Iron deficiency anemia | Withdrawn | |||
| TBC | risperidone | Schizophrenia, adults | Suspended | |||
| TBC | ruxolitinib | atopic dermatitis | Suspended | |||
| TBC | tarlatamab | Extensive stage small cell lung cancer | Pending | |||
| TBC | garadacimab | Hereditary angioedema (HAE) | Pending |
Last Updated : July 28, 2024